Piero Sismondi
Piero Sismondi
affiliation: Università di Torino
research area(s): Experimental Medicine, Cancer Biology
Course: Biomedical Sciences and Human Oncology
University/Istitution: Università di Torino
Full Professor of Gynecological Oncology

The full list of publications is available at the following link. www.publicationslist.org/piero.sismondi
Piero Sismondi is Full Professor of Gynecological Oncology, Director of the Postgraduate School in Obstetrics and Gynaecology at the University Medical School, in Torino, Italy and Head of the Academic Division of Obstetrics and Gynaecology, Gynecologic Oncology and Breast Diseases at the Mauriziano Hospital in Torino, Italy.
Dr. Sismondi completed his MD and specialist training in obstetrics and gynecology and clinical oncology at the University of Torino Medical School, followed by a fellowship at the Institute Gustave-Roussy in Paris, France, and clinical fellowships in the USA (including the Memorial Sloan-Kettering Cancer Center in New York, the University of Texas M. D. Anderson Cancer Center, the Jackson Memorial Hospital in Miami and the UCI in Irvine), specializing in breast and pelvic surgery and oncology.
Dr Sismondi has participated in several clinical trials, including those investigating the clinical relevance of tissue and serum prognostic markers in the management of breast cancer, and the role of estrogen receptors as predictors of response to hormonal treatments. He has developed a special interest in the relationship between hormonal influences and breast cancer risk, and is involved in several biological and clinical studies concerning the safety of hormonal replacement therapy in breast cancer survivors. In 1993 he has developed, together with professor Daniel Chassagne and other Colleagues a glossary of complications of gynecologic cancer treatments that is still the reference standard for complications reporting.
Dr Sismondi is member of many Scientific Societies, of the Torino Academy of Medicine and of the New York Academy of Sciences; is a founding member of the Société Française d'Oncologie Gynécologique, and the International Gynecologic Cancer Society. He acted as President of the Italian Society for Gynecological Oncology and of the Italian Menopause Society, as counselor and secretary of the European Society of Gynecological Oncology.
N Biglia, V E Bounous, L Martincich, E Panuccio, V Liberale, L Ottino, R Ponzone, P Sismondi (2011) Role of MRI (magnetic resonance imaging) versus conventional imaging for breast cancer presurgical staging in young women or with dense breast. Eur J Surg Oncol 37: 3. 199-204 Mar
PMID Emilia Parodi, Alessandra Alluto, Giulia Moggio, Viola Liberale, Mario Frigerio, Piero Sismondi (2011) Transient ventricular hypocinesia after in utero anthracyclines exposure: a case-report and review of the literature. J Matern Fetal Neonatal Med Mar
PMID Nicoletta Biglia, Elisa Peano, Paola Sgandurra, Giulia Moggio, Enrico Panuccio, Marco Migliardi, Nicoletta Ravarino, Riccardo Ponzone, Piero Sismondi (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 26: 6. 404-412 Jun
PMID Francesco Boccardo, Dino Amadori, Pamela Guglielmini, Piero Sismondi, Antonio Farris, Biagio Agostara, Angelo Gambi, Giuseppina Catalano, Marina Faedi, Alessandra Rubagotti (2010) Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Oncology 78: 3-4. 274-281 06
PMID Angiolo Gadducci, Nicoletta Biglia, Stefania Cosio, Piero Sismondi, Andrea Riccardo Genazzani (2010) Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol 26: 8. 568-577 Aug
PMID Nicoletta Biglia, Giulia Moggio, Elisa Peano, Paola Sgandurra, Riccardo Ponzone, Rossella E Nappi, Piero Sismondi (2010) Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 7: 5. 1891-1900 May
PMID C Tinterri, W Gatzemeier, V Zanini, L Regolo, C Pedrazzoli, E Rondini, C Amanti, G Gentile, M Taffurelli, P Fenaroli, C Tondini, G Sacchetto, P Sismondi, R Murgo, M Orlandi, E Cianchetti, C Andreoli (2009) Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. Breast 18: 6. 373-377 Dec
PMID Riccardo Ponzone, Nicoletta Tomasi Cont, Furio Maggiorotto, Elisa Cassina, Paola Mininanni, Nicoletta Biglia, Piero Sismondi (2009) Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer. J Clin Oncol 27: 33. 5547-5551 Nov
PMID Peter Kenemans, Nigel J Bundred, Jean-Michel Foidart, Ernst Kubista, Bo von Schoultz, Piero Sismondi, Rena Vassilopoulou-Sellin, Cheng Har Yip, Jan Egberts, Mirjam Mol-Arts, Roel Mulder, Steve van Os, Matthias W Beckmann (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10: 2. 135-146 Feb
PMID N Biglia, P Sgandurra, E Peano, D Marenco, G Moggio, V Bounous, N Tomasi Cont, R Ponzone, P Sismondi (2009) Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric 12: 4. 310-318 Aug
PMID P De Iaco, A Ferrero, F Rosati, M Melpignano, N Biglia, M Rolla, D De Aloysio, P Sismondi (2009) Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol 35: 6. 643-648 Jun
PMID Francesca Orso, Richard Jäger, Raffaele Adolfo Calogero, Hubert Schorle, Piero Sismondi, Michele De Bortoli, Daniela Taverna (2009) AP-2alpha regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase. BMC Biol 7: 1. 05
PMID R Ponzone, E Cassina, N Tomasi Cont, N Biglia, P Sismondi (2009) Decreasing arm morbidity by refining axillary surgery in breast cancer. Eur J Surg Oncol 35: 4. 335-338 Apr
PMID Maria Silvia Giretti, Xiao-Dong Fu, Giovanni De Rosa, Ivana Sarotto, Chiara Baldacci, Silvia Garibaldi, Paolo Mannella, Nicoletta Biglia, Piero Sismondi, Andrea Riccardo Genazzani, Tommaso Simoncini (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3: 5. 05
PMID Daniela Cimino, Luca Fuso, Christian Sfiligoi, Nicoletta Biglia, Riccardo Ponzone, Furio Maggiorotto, Giandomenico Russo, Luigi Cicatiello, Alessandro Weisz, Daniela Taverna, Piero Sismondi, Michele De Bortoli (2008) Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer 123: 6. 1327-1338 Sep
PMID N Biglia, L Mariani, R Ponzone, P Sismondi (2008) Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers. Maturitas 60: 2. 71-77 Jun

Project Title:
Breast cancer and hormone responsivity: new prognostic and predictive factors. Validation on retrospective and prospective series.
Endogenous sex steroids and their cellular receptors have an important role in the development of breast cancer, the most common tumor in women: 80% of breast cancers are hormone-responsive. The evaluation of the biomarkers estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor type 2 (Her2), androgen receptor (AR) and of the proliferation index score, Ki-67, in addition to traditional prognostic factors including nodal status, tumor size, etc. is very important in defining prognosis. Although antiestrogenic endocrine therapy is very effective either as adjuvant and as second line treatment, about 30% of hormone responsive breast cancers appears resistant to antiestrogenic endocrine therapy. Several studies show that response to endocrine therapy may be recovered by a sequential use of different agents. Recently, the genomic analysis with DNA microarray technology has allowed the identification of gene expression patterns correlated with the development of resistance to the endocrine therapy. The proteins encoded by these genes or the macromolecules produced following their transcription and released in the extracellular fluids might be used as serum markers of response to the endocrine therapy. The aim of the Unity of Clinical Research (UO2) is the validation of a set of markers, previously identified by UO1 and UO3 with different techniques, which would allow to early detect the development of resistance to the endocrine therapy thus changing the therapeutic strategy before the appearance of signs and symptoms of disease progression. Therefore, the UO2 will provide samples of breast tissue of patients with ER/PR postive breast carcinoma surgically treated from 2003: for this large retrospective study population, information about tumor and survival status are recorded in a dedicated data base, during periodical follow up controls. The UO2 will also provide breast tissue of a prospective sample of patients.
The role of androgens and AR in breast carcinoma is not totally clear. The predictive and prognostic significance of serum level of androgens in ER/PgR positive breast cancers will be analyzed; relationship between registered blood level of androgens in patients and the response to endocrine therapy, especially in aromatase inhibitors group, will be studied with particular care.